US Stock MarketDetailed Quotes
INZY Inozyme Pharma
- 5.540
- +0.210+3.94%
Close Jul 22 16:00 ET
- 5.540
- 0.0000.00%
Post 16:20 ET
342.68MMarket Cap-4103P/E (TTM)
5.555High5.202Low164.61KVolume5.370Open5.330Pre Close897.31KTurnover0.43%Turnover RatioLossP/E (Static)61.86MShares7.79552wk High2.88P/B210.01MFloat Cap2.68952wk Low--Dividend TTM37.91MShs Float31.650Historical High--Div YieldTTM6.62%Amplitude0.991Historical Low5.450Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Inozyme Pharma Stock Forum
NEWS
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
Inozyme Pharma (Nasdaq: INZY) announced that it will present topline data from its Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency at two upcoming medical conferences. The presentations will occur at the European Calcified Tissue Society Congress (ECTS)...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
No comment yet